Thomas Leonard
Director/Board Member bij NUGENEREX IMMUNO-ONCOLOGY, INC.
Profiel
Thomas Leonard is an Independent Director at NuGenerex Immuno-Oncology, Inc. He previously worked as a Manager-Oncology Northeast Business at Bristol Myers Squibb Co. He holds a graduate degree from New York University and an undergraduate degree from St. John's University.
Actieve functies van Thomas Leonard
| Bedrijven | Functie | Begin |
|---|---|---|
| NUGENEREX IMMUNO-ONCOLOGY, INC. | Director/Board Member | - |
Eerdere bekende functies van Thomas Leonard
| Bedrijven | Functie | Einde |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Opleiding van Thomas Leonard
| New York University | Graduate Degree |
| St. John's University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
NuGenerex Immuno-Oncology, Inc.
 NuGenerex Immuno-Oncology, Inc. BiotechnologyHealth Technology NuGenerex Immuno-Oncology, Inc. is an oncology company focuses on the modulation of the immune system to treat cancer. It develops immunotherapeutic products and vaccines based on proprietary, patented platform technology, Ii-Key. The Ii-Key is a peptide derived from the major histocompatibility complex (MHC) class II associated invariant chain that regulates the formation, trafficking, and antigen-presenting functions of MHC class II complexes, essential for the activation of T cells in the immune response. The company was founded on October 8, 1993 and is headquartered in Miramar, FL. | Health Technology |
